Go Pro
NASDAQ:XTLB

XTL Biopharmaceuticals Q4 2025 Earnings Report

XTL Biopharmaceuticals logo
$2.56 -0.10 (-3.76%)
As of 02:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

XTL Biopharmaceuticals EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
($0.26) million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XTL Biopharmaceuticals Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

XTL Biopharmaceuticals Earnings Headlines

My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
XTL Completed the Acquisition of Psyga Bio Ltd.
See More XTL Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

View XTL Biopharmaceuticals Profile